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Abstract: Glutamine synthetase (GS) is a cytosolic enzyme that produces glutamine, the most
abundant free amino acid in the human body. Glutamine is a major substrate for various metabolic
pathways, and is thus an important factor for the functioning of many organs; therefore, deficiency
of glutamine due to a defect in GS is incompatible with normal life. Mutations in the human GLUL
gene (encoding for GS) can cause an ultra-rare recessive inborn error of metabolism—congenital
glutamine synthetase deficiency. This disease was reported until now in only three unrelated patients,
all of whom suffered from neonatal onset severe epileptic encephalopathy. The hallmark of GS
deficiency in these patients was decreased levels of glutamine in body fluids, associated with chronic
hyperammonemia. This review aims at recapitulating the clinical history of the three known patients
with congenital GS deficiency and summarizes the findings from studies done along with the work-up
of these patients. It is the aim of this paper to convince the reader that (i) this disorder is possibly
underdiagnosed, since decreased concentrations of metabolites do not receive the attention they
deserve; and (ii) early detection of GS deficiency may help to improve the outcome of patients who
could be treated early with metabolites that are lacking in this condition.
Keywords: glutamine synthetase; rare disease; GLUL; epileptic encephalopathy; GS deficiency;
glutamine-glutamate-GABA; hyperammonemia; inborn error of metabolism
1. Introduction
Glutamine synthetase (GS) is a cytosolic enzyme that produces glutamine, the most abundant
free amino acid in the human body. Glutamine is a major substrate for various metabolic pathways,
and is thus an important factor for the functioning of many organs; therefore, deficiency of glutamine
due to a defect in GS is incompatible with normal life. In fact, mutations in the gene encoding the
mitochondrial glutamine synthetase I (GSI) of Drosophila melanogaster resulted in embryo-lethal female
sterility [1] and, likewise, GS was found to be essential in early embryogenesis in mice [1]. It was
thus interesting to learn that mutations in the human GLUL gene (OMIM *138290), encoding for
GS, can cause an ultra-rare recessive inborn error of metabolism—congenital glutamine synthetase
deficiency (OMIM #610015). This disease was reported until now in only three unrelated patients,
all of whom suffered from neonatal onset severe epileptic encephalopathy [2–4]. The hallmark of GS
deficiency in these patients was decreased levels of glutamine in body fluids, associated with chronic
hyperammonemia. Although the number of patients with this condition is very small, many lessons
could be learned from an investigation of their cases. This review aims at recapitulating the clinical
history of the three known patients with congenital GS deficiency and summarizes the findings from
studies done along with the work-up of these patients. It is the aim of this paper to convince the reader
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that (i) this disorder is possibly underdiagnosed, since decreased concentrations of metabolites do not
receive the attention they deserve; and (ii) early detection of GS deficiency may help to improve the
outcome of patients who could be early treated with metabolites that are lacking in this condition.
2. Clinical Presentation of Inherited Glutamine Synthetase Deficiency
Congenital glutamine synthetase deficiency is an ultra-rare disease, hitherto reported in only
three unrelated patients since its first description in 2005 [2–4]. All of the patients were offspring of
consanguineous parents. Two patients had Turkish origin (denoted here as patient 1 and 2, Table 1);
the third patient was from Sudan (denoted as patient 3, Table 1). Although the survival time was
different among the three, the main clinical features were similar.
The initial phenotype was characterized by severe neonatal encephalopathy and by brain
malformations in patients 1 and 2, who underwent magnetic resonance imaging (MRI) of their brain
as neonates. These two patients were already severely neurologically compromised at birth, and
rapidly went into multiple organ failure. Patient 1 died on day 2 of life, while patient 2 lived for
four weeks before succumbing to multiple organ failure. In addition to the encephalopathy, this
second patient suffered from a severe gastrointestinal disorder with voluminous diarrhea during the
first weeks. During the course of her short life (and probably due to systemic glutamine deficiency),
she developed a generalized blistering erythema described on histologic examination as a necrolytic
migratory erythema [3]. The brain MRI of both of these patients showed general atrophy, marked
malformations, abnormal gyration, and white matter lesions. The post-mortem examination of patient
1 revealed a small brain (weight 202 g, while 335 g was expected for the respective gestational age).
In the third patient (patient 3), the presentation and clinical course differed in comparison to the
other patients. At birth, Apgar scores were 9 and 10 at 1 and 5 min, and his clinical examinations
were all normal, apart from the neurological testing that showed generalized muscular hypotonia,
lower limb hyperreflexia, clonus, and staring of the eyes lasting for 2–3 min. At the age of 13 days, he
developed drug-resistant generalized tonic–clonic seizures, and his further neurological development
was markedly delayed. Brain MRI at the age of 11 and 28 months showed mild to moderate brain
atrophy and hypomyelination of the white matter. He had multiple hospital admissions due to
uncontrolled seizures, frequent apnea, and recurrent upper and lower airway infections. At 11 months
of age, attacks of seizures with bradycardia and desaturation necessitated mechanical ventilation
and later a tracheostomy. Furthermore, at 38 months of age, this patient suffered from a single short
episode of necrolytic erythema lasting only few days during a period with very low blood glutamine
levels [4]. This patient received a trial of enteral glutamine supplementation (described below) [5] and
finally died at six years of age from an acute respiratory decompensation.
3. Biochemical Presentation
3.1. Physiology and Pathophysiology
Glutamine—the most abundant free amino acid in the human body—plays a major role in essential
metabolic pathways such as nitrogen metabolism, ammonia detoxification, acid–base homeostasis,
osmotic regulation, and cell signaling and proliferation [6–10].
The diagnosis of GS deficiency is suggested if decreased levels of glutamine in any body fluid are
found. The three patients described here were diagnosed by severely decreased glutamine levels in
plasma and cerebrospinal fluid (CSF). Interestingly, however, in patient 3, the levels of glutamine in
plasma and CSF were normal when first investigated in early infancy, but decreased during the course
of the disease [4].
Glutamine is a precursor for neurotransmitters and a substrate for immune cells [6,11–13].
Moreover, it is a precursor for glucose, purines, pyrimidines, adenosine monophosphate, and
nicotinamide adenine dinucleotide (NAD+) [9,14–16]. It is also a substrate for transamination reactions
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required for the production of α-ketoglutarate, closure of the methionine salvage pathway, and salvage
of α-keto acids [17].
Table 1. Main clinical features and diagnostic analysis of patients with glutamine synthetase
(GS) deficiency.
Variable Patient 1 [2] Patient 2 [2] Patient 3 [4]
Ethnicity/Gender Turkish boy Turkish girl Sudanese boy
Prenatal
ultrasonography
Polyhydramnios, large lateral
brain ventricles with a left
frontal paraventricular cyst,
micromelia
Dilatation of cerebral
posterior fossa
Delayed gyration, marked
white matter changes,
subependymal cysts
Presentation at
birth
Spontaneously at 354/7 week Spontaneously at 386/7 week Term
Birth weight
Length
Head circumfer.
2220 g (10th percentile)
44 cm (3rd–10th percentile)
34 cm (75th–90th percentile)
2460 g (3rd–10th percentile)
42 cm (<3rd percentile)
28.5 cm (<3rd percentile)
3245 g (50th percentile)
53 cm (90th percentile)
34 cm (50th percentile)
Clinical course Epileptic encephalopathy
Multiple organ failure
Epileptic encephalopathy
Multiple organ failure
Necrolytic erythema
Diarrhea
Epileptic encephalopathy
Severe developmental delay
Necrolytic skin erythema
(one episode)
Onset Immediately after birth Immediately after birth Day 1
Life Time 2 days 28 days 6 years
Dysmorphic
features
Flat nasal root, low-set ears,
flexion contractures at elbows
and knees, shortness of limbs
Broad nasal root, low-set ears None
EEG Generalized seizures,
Outbursts of theta waves
Multifocal seizures Generalized tonic-clonic
seizures
Brain MRI Cerebral and cerebellar atrophy,
almost complete agyria,
immature white matter, multiple
paraventricular cysts in frontal
and temporal lobes, enlarged
lateral ventricles
Small frontal lobe and
cerebellum, delayed gyration,
marked white matter changes,
subependymal cysts
Mild degree of brain atrophy
with prominent cortical sulci
and sylvian fissures,
hypomyelination of white
matter, thinning of the
corpus callosum
Glutamine
Serum 2 µmol/L
(normal range: 433–619)
6 µmol/L
(normal range: 300–800)
First test: 126 µmol/L,
range: 8–354 µmol/L
(normal range: 376–709)
Urine Not detectable
(normal range: 52–205)
8 µmol/g creatinine
(normal range: 640–3230)
Cerebrospinal
fluid
11 µmol/L
(normal range: 352–885)
12 µmol/L
(normal range: 520–1280)
Range: 50–238 µmol/L
(normal range: 373–556)
Glutamate
Serum 45 µmol/L
(normal range: 36–82)
80 µmol/L
(normal range: 70–220)
Range: 20–143 µmol/L
(normal range: 62–260)
Urine 2 mmol/mol creatinine
(normal range: 0–30)
34 µmol/g creatinine
(normal range: 0–250)
Cerebrospinal
fluid
Not detectable
(normal range: 1–48)
2 µmol/L
(normal range: 2–51)
Ammonia
Plasma 140 µmol/L
(normal < 110)
Mean: 94 µmol/L,
range: 38–424 µmol/L
(normal < 50)
Mutation
c.970C > T (p.R324C) c.1021C > T (p.R341C) c.970C > A (p.R324S)
The only way to produce glutamine in the mammalian organism is by endogenous condensation
of ammonia with glutamate [14], an ATP-dependent reaction catalyzed by the GS enzyme [18].
Glutamine from nutritional sources does not contribute to the systemic glutamine pool in healthy
individuals, as it is mainly metabolized directly upon absorption in the enterocytes of the small
intestine [19,20]. In GS deficiency, the small amount of glutamine that is still produced by the mutant
GS protein is probably immediately consumed by several metabolic pathways, resulting in chronic
systemic glutamine depletion. Medical conditions with pronounced protein catabolism (e.g., any
life-threatening illness, severe inflammation, or burns) can also lead to reduction of the systemic
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glutamine pool [9,21]. However, glutamine levels reported in such cases remain higher than those seen
in inherited GS deficiency [22].
3.2. Relation of Glutamine and Hyperammonemia
Intestinal degradation of protein from nutritional sources and the production of ammonia by
bacteria in the large intestine are main sources of the excess nitrogenous compounds that undergo
detoxification in the liver. As a consequence, the ammonia concentration in the portal vein is
significantly higher than in venous or arterial blood. The urea cycle and the action of GS are the
two main ammonia detoxifying systems, operating anatomically and functionally in sequence: in
periportal hepatocytes, the majority of the excess ammonia is incorporated into urea, while a much
smaller proportion that escapes the urea cycle is cleared in the perivenous hepatocytes, where it is used
for glutamine synthesis [23–25]. Accordingly, the Km for ammonia is 1–2 mM in urea cycle enzymes
but 0.3 mM in GS, underlining that GS provides a high affinity but low capacity ammonia removal in
contrast to the high capacity but low affinity system of the urea cycle [24]. Nevertheless, for a complete
ammonia detoxification, both systems are required, and the urea cycle alone is not sufficiently effective.
The critical role of GS in ammonia detoxification was confirmed by the rise of ammonia concentration
in the hepatic vein as well as in the brain after the inhibition of GS by methionine sulfoximine
(MSO, an inhibitor of the GS enzyme) in rats [26–28]. In line with this, a liver-specific GS knock-out
(KO) mouse model was found to develop hyperammonemia [29]. Not surprisingly, in patients with
GS deficiency, the decreased levels of plasma glutamine were accompanied by hyperammonemia.
In fact, hyperammonemia in these patients results from the insufficient capacity of the perivenous
cells to incorporate ammonia into glutamine [3,30]. Patient 2 had moderate hyperammonemia, and
patient 3 showed chronic hyperammonemia during his entire life (closely monitored in the first
43 months) [4]. Thus, these two characteristics—low glutamine levels and hyperammonemia—are the
main biochemical signs found in patients with GS deficiency (details in Table 1).
3.3. Glutamine Synthetase Activity and Expression
GS catalyzes the formation of glutamine in a two-step reaction: Glutamate + ATP→ γ-glutamyl
phosphate + NH4+ → glutamine + ADP + Pi [18,24] (Figure 1). The rate of the enzymatic reaction
depends on cofactor availability (divalent metal ions), substrate supply, and GS expression levels and
activity [3].
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In two patients (patients 1 and 2), GS activity was strongly reduced, as measured in 
immortalized lymphocytes from patient 1 and in COS7 cells transfected with the mutated GS from 
patient 2 [2,31]. Investigations on fibroblasts from patients 1 and 2 were not possible, since they failed 
to grow (other GS-deficient fibroblasts required a high-glutamine-containing medium to grow). The 
longer survival of patient 3 could be related to the higher levels of glutamine synthesis as compared 
to the other patients (Table 1), suggesting that a slightly higher enzymatic activity of GS was retained 
in this specific patient. Hence, higher glutamine levels achieved by supplementation can be beneficial. 
A significant increase of the levels of GS expression was observed in immortalized lymphocytes from 
patient 1 or in fibroblasts from patient 3 (only for this patient, skin cells survived in a standard 
Figure 1. The reaction of glutamine synthetase. Schematic representation of the two-step reaction
catalyzed by glutamine synthetase to form glutamine using glutamate, ATP, and ammonia as substrates.
The phosphate originating from ATP is depicted in red, ammonium in blue.
In two patients (patients 1 and 2), GS activity was strongly reduced, as measured in immortalized
lymphocytes from patient 1 and in COS7 cells transfected with the mutated GS from patient 2 [2,31].
Investigations on fibroblasts from patients 1 and 2 were not possible, since they failed to grow (other
GS-deficient fibroblasts required a high-glutamine-containing medium to grow). The longer survival of
patient 3 could be related to the higher levels of glutamine synthesis as compared to the other patients
(Table 1), suggesting that a slightly higher enzymatic activity of GS was retained in this specific patient.
Hence, higher glutamine levels achieved by supplementation can be beneficial. A significant increase of
the levels of GS expression was observed in immortalized lymphocytes from patient 1 or in fibroblasts
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from patient 3 (only for this patient, skin cells survived in a standard medium). This likely reflects
an up-regulation mechanism to compensate the low levels of glutamine caused by the diminished
enzymatic activity of the mutant GS [2]. This up-regulation could not fully compensate the glutamine
deficiency in patients, but may have allowed some pre- and postnatal development, since a complete
loss of GS function would not be compatible with survival [1,32–34].
GS activity can be compromised not only by inherited defects, but also in a secondary
way by posttranslational modifications, such as tyrosine nitration. Excessive ammonia exposure
causes the formation of nitric oxide (NO), which interacts with superoxide anions formed in the
mitochondria [35,36]. This leads to the creation of highly toxic peroxynitrites, which interact with tyrosine
residues of GS [37,38]. In vivo experiments with inducible GS tyrosine nitration in rat hepatocytes
showed a decrease of 20% in GS expression and 40%–50% in its activity [39]. Thus, GS tyrosine
nitration, observed as a result of chronic hyperammonemia [39–41], would explain the decreasing
plasma glutamine levels observed in a single patient with GS deficiency (patient 3) [4,36,39].
In rat brain, GS activity can be reduced by NO in astrocytes [42]. In contrast, increased
glutamate—by blocking N-methyl-D-aspartate (NMDA) receptors or inhibition of NO synthesis
(by blocking NO synthase) in vivo—caused an increase of the GS activity and glutamine content in the
rat brain [42,43]. Other posttranslational modifications currently studied (such as lysine acetylation of
GS) may contribute to the regulation of GS expression. In this case, high glutamine concentrations
would cause conformational changes in the protein, exposing the N-terminal domain to acetylation
(at lysine residues 11 and 14) to create a signal triggering the enzyme into the degradation pathway [44].
GS function is also regulated by many other factors, including β-catenin activation [45,46],
hormonal regulation [47–51], pH variation [9,52], oxidative stress [40,53], glucose deprivation [54],
ischemia [55,56], or glutamine concentration in culture medium [57]; however, a detailed description
is beyond the scope of this mini-review.
4. Molecular Genetics of Glutamine Synthetase Deficiency
The glutamate-ammonia ligase (GLUL) gene is highly conserved within living organisms, and is
known to be one of the oldest existing genes [58]. In humans, GLUL maps to 1q31 [59], and covers
10 kb (Ensembl, ENSG00000135821). One pseudogene and three GLUL-like genes have been described,
but their function is not fully understood [60]. GLUL transcript consists of 1122 bp, it covers 4065 bp
(Ensembl, ENST00000417584) comprising six exons encoding a 373 amino-acid polypeptide [2].
Sequence analysis showed three different homozygous missense mutations in GLUL exon 6:
p.Arg324Cys in patient 1, p.Arg341Cys in patient 2, and p.Arg324Ser in patient 3 (details in Table 1).
Parental heterozygosity suggested an autosomal recessive mode of inheritance [2].
Another case of suspected GS deficiency was recently reported to our laboratory in a five
year old Russian boy with a severe epileptic encephalopathy progressing since the age of
three months. By whole exome sequencing (Centogene, Rostock, Germany), two probably damaging
mutations—c.584C > A (p.Ala195Asp) and c.956G > A (p.Arg319His)—were found. However, only
the father was a carrier of one of the mutations, but not the mother. Besides, the patient had normal
glutamine levels according to tandem mass-spectrometry analysis using dried blood spots. It was
therefore necessary to confirm the phase of the variants (cis or trans), since a double-mutated allele
in combination with a wild-type allele was suspected. Thus, in our lab we performed allele-specific
long-range polymerase chain reaction (PCR) and Sanger sequencing of GLUL in this family. The results
suggested the presence of the mutations on the same allele, so the diagnosis of a GS deficiency could
not be made in this patient. However, since the two variants are probably disease-causing (see below),
they are included in this list of known GLUL mutations, and in the structural considerations below.
5. Structure of Glutamine Synthetase and Rationalization of the Clinical Mutations
Human GS is a homodecameric protein composed of two pentameric rings stacked to each
other (Figure 2A,B). A bifunnel-shaped catalytic site is formed at each interface between two adjacent
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monomers, adding up to a total of ten catalytic sites per molecule [61]. The association-dissociation
process of the monomers of the GS enzyme (as analyzed in the ovine brain in vitro) is regulated by the
concentration of the GS protein, substrate, and metal ions [62].
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Glutamine is formed via a two-step reaction (Figure 1). In the first step, ATP binds GS, leading
to a conformational change that enables glutamate binding. Once glutamate is bound, the terminal
phosphate group of ATP is transferred to the γ-carboxylate group of glutamate, producing ADP and
γ-glutamyl phosphate (GGP). In the second step, an ammonium ion binds, transfers a proton to Asp63,
and the ammonia thus formed attacks GGP. This yields an inorganic phosphate and a positively
charged intermediate that is stabilized by Glu305 via a salt bridge interaction. Lastly, Glu305 gets
protonated, destabilizing the salt bridge and leading to the opening of glutamate binding site and to
glutamine release [63].
Two of the clinical mutations known—p.Arg324Cys (in patient 1) and p.Arg324Ser (in patient 3)—affect
a highly-conserved residue [64], Arg324. The prediction server PolyPhen gives predictions of “possibly
damaging” for both mutations, and the prediction server MutPred gives values of 0.960 and 0.908
(indicating pathogenicity), respectively. In fact, mutant p.Arg324Cys exhibited 12% of the wild-type
enzyme activity when measured in immortalized lymphocytes [2], and p.Arg324Ser conserved certain
residual activity [5]. This arginine (Arg324), located in each catalytic site, forms an ionic salt bridge
with the β-phosphate group of the ADP in the crystal structure (Figure 2C; PDB file 2QC8, [61]), and
Biology 2016, 5, 40 7 of 17
therefore will probably be involved in the binding of ATP in the reaction of glutamine synthesis.
Thus, removal of this arginine will presumably hamper ATP binding, explaining the decreased
enzyme activity observed in both mutant forms [2,5]. Besides, since p.Arg324Cys and p.Arg324Ser
had increased expression levels in cell culture studies [2,31], these mutants probably lead to lower
catalytic efficiency. It is also to be highlighted that, in homozygosis, p.Arg324Cys was fatal in the
neonatal period, while p.Arg324Ser was found in a patient still alive at the age of 6 years. In silico
modeling of these two mutant forms predicted an attenuated effect of mutant p.Arg324Ser as a result
of water-mediated interactions with ATP [63].
Regarding p.Arg341Cys, the prediction servers give calculations of “possibly damaging”
(PolyPhen) and 0.920 (MutPred). This mutation affects an arginine conserved in all eukaryotes [64], and
its activity measured in transfected COS7 cells was significantly reduced (to ~58% of the wild-type) [2].
In the crystal structure, Arg341 forms a triad with Asp339 and Arg340 (Figure 2D). This last arginine
(Arg340) makes a hydrogen bond and a salt bridge with the sulfoximine group of methionine
sulfoximine phosphate (MSO-P) (Figure 2D), a molecule used in the crystal structure to simulate
the positioning of glutamate. In addition, the guanidine group of Arg341, pointing away from
the catalytic center, establishes hydrogen bonds with His281, His284, and Tyr288, all localized in
helix 8 (H8) (Figure 2D). Upon ATP binding (in the first step of the catalysis), this helix undergoes
a conformational change, leading to the closure of the GS catalytic site, which has been proven to
be essential for glutamate binding [61]. For these two reasons, it was suggested that the removal of
Arg341 may hamper glutamate binding to GS [63], in line with the observed decreased activity of the
mutant form p.Arg341Cys [2].
Next, the novel mutation p.Arg319His was predicted to be probably damaging (PolyPhen) and
received a value of 0.929 (indicating pathogenicity) by MutPred. Arg319 is a conserved arginine in all
known species [61], highlighting its essential role. In the crystal structure, this arginine belongs to the
secondary elements that undergo a major conformational change near the active site upon substrate
binding (amino acids 311–337) (PDB file 2QC8) [61]. In fact, Arg319 binds the phosphate group of
MSO-P (Figure 2C) [61], which indicates the direct involvement of this arginine in glutamate binding.
p.Arg319His was found in the same allele together with p.Ala195Asp in the child with suspicion of GS
deficiency (not confirmed, as described above). For this second mutation, the prediction servers gave
calculations of “possibly pathogenic” (PolyPhen) and 0.722 (MutPred). Ala195, in spite of not binding
directly any of the substrates, is localized in a loop forming one of the walls of the substrate-binding
cavity (Figure 2C) [61]. Its neighboring residue Glu196 is involved in binding one of the three Mn2+ ions
in the active site (known as n1). In the apo structure of GS of Canis familiaris, n1 hosts only one divalent
cation. Its positive charge serves to compensate for the charges on the three acidic residues involved
in catalysis (glutamates 136, 196, and 203) [61]. Thus, the introduction of another negative charge
provided by the aspartate (p.Ala195Asp) into this complex network of charges will lead to an imbalance
of charges, probably displacing these key glutamates, thus hampering catalysis. In conclusion, these
two mutations found in the same allele in this child will probably exhibit additive effects, having
an even greater impact on the mutant enzyme. However, this child still carried a wild-type allele,
which ensures him normal levels of systemic glutamine.
6. Pathophysiology of Glutamine Synthetase Deficiency
Despite its expression in many organs, the main clinical pathology in GS deficiency is
related to the central nervous system, where GS is mainly expressed in both astrocytes and
oligodendrocytes [65–67], but also in Müller cells of the retina [68], ependymal cells, and in nitrergic
neurons [69]. GS plays a key role in (i) protecting the neurons from excitotoxicity by capturing
ammonia and glutamate in the glial cells; and (ii) supplying glutamine for glutamate and GABA
synthesis in the glutamine-glutamate-GABA cycle, regulating the excitatory and inhibitory synaptic
transmission of neurons (Figure 3) [6,70,71]. Here, we will only briefly discuss the pathophysiology in
relation to GS deficiency, but the reader is referred to more dedicated work for complete insight.
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6.1. Cerebral Ammonia Toxicity in GS Deficiency
In the brain, ammonia is produced by the reactions of glutaminase and glutamine
dehydrogenase [6]. In addition, ammonia from the body circulation can diffuse across the blood-brain
barrier, entering astrocytes, where it is normally rapidly detoxified by incorporation into glutamine
(Figure 3) [15,47,72]. The GS reaction, together with phosphate-activated glutaminase (PAG), ensures
the transfer and regulation of ammonia between neurons and astrocytes [73]. In fact, the reaction driven
by GS (and obviously impaire in an inherited defect of this enzyme) is the main mechanism in the
brain for removing ammonia [6,26,74]. Any excess of ammonia is toxic for the cerebral cells, by multiple
echanis s. This includes direct toxic effects, such as oxidative/nitrosative stress due to disturbance
of the NO pathway, creatine deficiency, and inhibition of the tricarboxylic acid cycle (TCA). These toxic
effects can lead to secondary mitochondrial failure, and thus, energy deficit. For a complete picture,
the reader is referred to the following reviews [38,47,74,75]. Additionally, the similarity between NH4+
and K+ may lead to an increased up-take of ammonium and water, mediated by the Na+/K+-ATPase
and NKCC1, a co-transporter of Na+, K+, 2 Cl−, and water, contributing to cerebral edema formation
during hyperammonemia [75]. By impairing astrocyte potassium buffering, hyperammonemia was
found to favor depolarization of GABA neurons, leading to the impairment of the cortical inhibitory
network and seizures [75,76]. Histopathologic investigations initially performed on rats with hepatic
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encephalopathy showed RNA oxidation as a result of elevations in ammonia [41,77]. This was
further confirmed in liver-specific GS-deficient KO mice. These mice preserved normal glutamine
concentrations in the brain, but showed (due to hyperammonemia) high levels of oxidized RNA in
Purkinje cells of the cerebellum, in the hippocampus, and the somato-sensory cortex [29].
According to the “Trojan horse” hypothesis, in hyperammonemic conditions, glutamine (the
Trojan horse) serves as a carrier of excessive ammonia into the cytoplasm and into the mitochondria
of the astrocytes, causing mitochondrial permeability transition (MPT) [78–81]. This hypothesis was
however discussed because a rise of ammonia was not confirmed in magnetic resonance spectroscopy
(MRS) studies with [15N] in rats in acute hyperammonemic conditions in vivo. Further, the resulting
losses of ATP secondary to MPT were not noted in the hyperammonemic brain [28]. Besides, since
the increase of cellular ammonia in the Trojan horse hypothesis relies on the increased production of
glutamine in the GS reaction, it may not be present in patients with GS deficiency. Still, this possibility
has to be considered during glutamine supplementation, and renders careful ammonia monitoring
advisable during the initiation of glutamine therapy in GS-deficient patients.
6.2. Neurotransmission in Glutamine Synthetase Deficiency
Glutamine is a substrate for glutamate and GABA synthesis in glutaminergic and GABAergic
neurons, respectively, and therefore, it contributes to the regulation of the glutamine-glutamate-GABA
cycle compartmentalized between neurons and astrocytes (Figure 3) [6,71,72,75,82]. This was confirmed
by nuclear MRS using 13C glutamine [71,83–85] and by immunochemical studies, where inhibition of
GS with MSO increased the level of glutamate in glial cells [11,86]. Further, whole brain metabolites
analysis in rats showed that inhibition of GS with MSO decreases the whole glutamate brain pool [6].
Since the availability of glutamine is essential for GABA and glutamate synthesis [71], low
glutamine levels in GS deficiency may be insufficient to replenish the glutamate and GABA neuronal
pools [87]. As reported in patient 3, glutamine levels in the CSF and on MRS of basal ganglia were very
low [5], but could be enhanced by glutamine supplementation, likely improving levels of glutamine in
the glutamatergic and GABAergic neurons [5]. This was suggested by the finding of increased brain
glutamine and glutamate in the treated GS-deficient patient, although CSF and MRS measurements
only partially reflect the neurotransmitter pool [88]. The failure to completely correct the biochemical
brain phenotype may, however, be due to brain atrophy as a result of neurodegeneration [5].
Several studies have shown that the inhibition of GS as well as hyperammonemia can lead
to an elevation of extracellular glutamate levels [82,89,90], which clinically is often associated with
seizures through the activation of the NMDA receptor [38]. However, the concentrations of glutamate
were not elevated in the plasma or CSF of patients with GS deficiency, and were even slightly
decreased on MRS in patient 3 [5]. Nevertheless, a general impairment of astrocyte function due to
glutamine deficiency and hyperammonemia in the patients may lead to a failure of the regulation of
neuronal homeostasis and disturbance of the excitation-inhibition balance [91]. Astrocyte dysfunction
may thus contribute to abnormal neuronal activity and seizures, leading to severely abnormal
electroencephalography (EEG) recordings in GS-deficient patients. In line with this, glutamine
supplementation could improve the seizure activity in patient 3 [5]. Further, supporting the role
of exogenous glutamine administration, selective viral induction of astrocytic gliosis in a hippocampal
region of mouse brain led to a failure of the glutamine-glutamate-GABA cycle and reduced inhibitory
synaptic current that could be reversed by glutamine [92].
6.3. Fetal Development in Glutamine Synthetase Deficiency
GS is already expressed in early fetal stages [87]. Its activity varies during fetal development, but
is essential for early embryogenesis, as shown by the lethality of complete KO mice at only day 3.5 of
embryonic development [87]. In addition, in the same study, the embryonic mice could be rescued by
glutamine supplementation [87].
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During pregnancy, the developing fetus utilizes large amounts of glutamine derived from
maternal blood or obtained from endogenous placental synthesis [32,93], which may however be
insufficient for a GS-deficient fetus. In human fibroblasts, glutamine was proven essential during
fetal development for cellular proliferation [34]. Glutamine and glutamate are also important
for the developing brain, in the organization of neural differentiation and proliferation [53,94].
An insufficient supply of glutamine during the embryonic period probably favors white matter
changes and brain malformations, as observed on the cerebral MRI of the three patients (Table 1).
Interestingly, Cre-mediated astrocyte-specific GS-deficient mice showed glutamine deficiency and
increased ammonia in the cerebral tissues, but did not show brain malformation at birth [87].
One possible explanation is that the late elimination of the GS—completed at only 18 days of fetal age
in this experiment—may have still allowed early brain development. Further underlining the role
of glutamine for the glutamine-glutamate-GABA cycle and glial differentiation during the peri- and
postnatal period is the fact that mice deficient in glutamine died three days after birth [87,95].
6.4. NAD+ Depletion in Glutamine Synthetase Deficiency
Due to the key role of GS and glutamine for the human organism, its deficit can have an impact on
many metabolic pathways. It has been noticed that two of the patients presented necrolytic erythema
associated with very low plasma glutamine levels. The histological lesions of one patient (patient 2)
were reminiscent of pellagra, a disease caused by niacin deficiency [3]. Niacin itself is one of the
precursors of nicotinamide adenine dinucleotide (NAD+) [96,97]. NAD+ (and its phosphorylated
and reduced forms, NADP+, NADH, and NADPH) is a coenzyme involved in vital oxido-reduction
reactions found in all living cells [98,99]. We had the opportunity to investigate the availability of
NAD+ in one patient with inherited GS deficiency (patient 3) to follow-up on the hypothesis of a NAD+
deficiency in patients with systemic glutamine deficiency. Unsurprisingly, NAD+ was found to be
severely lacking in cultured fibroblasts, immortalized peripheral blood stem cells, and in leukocytes
both in vitro and in vivo [31]. Consequently, it was speculated that the NAD+ deficiency contributed
to the global severity of the disease. Indeed, glutamine is a nitrogen provider for NAD+ synthesis by
NAD+ synthetase; thus, lack of glutamine may contribute to NAD+ deficiency found in patients [100].
Furthermore, this observation could open the possibility of a novel therapeutic intervention to alleviate
the devastating phenotype in GS deficiency. Exogenous supplementation with either glutamine or
NAD+ precursors (nicotinamide or nicotinate) in fibroblasts in vitro normalized the intracellular NAD+
concentration [31]. The same was observed in vivo when the GS-deficient patient received glutamine
over four weeks, resulting in a marked increase in NAD+ levels in leukocytes [31].
7. Secondary Glutamine Synthetase Deficiency
Secondary deficiency of GS function has been associated with a broad range of human diseases.
As underlying cause, a disturbance of nitrogen metabolism or impaired GS activity and expression were
hypothesized to contribute to the development of different neurological diseases such as Alzheimer’s,
schizophrenia, and mesial temporal lobe epilepsy (MTLE, described below). However, all of these
probably result from different perturbations of the posttranslational modifications of GS.
In the case of Alzheimer’s disease, it was hypothesized that GS is vulnerable to either
age-related oxidation or to the action of β-amyloids (in the frontal cortex), which would lead
to a decrease in its activity [101,102]. An increased expression of GS would be associated with
increasing levels of Alzheimer-type pathology in the aging brain, as a reaction to the activation of
phosphoinositide-3-kinase-FOXO signaling in astrocytes [103,104]. Additionally, the distribution of
the GS expression in the cerebral cortex is perturbed, and may be triggered by toxic agents in senile
plaques, reduced noradrenergic supply to the cerebral cortex, and increased brain ammonia levels [102].
The resulting secondary GS deficiency progressively leads to incomplete ammonia detoxification and
a gradual decline of the glutamine-glutamate-GABA cycle, causing impairment in synaptic connectivity
with deficient cognition and memory [102,105].
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Secondary GS deficiency in astrocytes of the sclerotic hippocampal formation was suggested to
be a possible molecular basis for MTLE. In this case, it is thought that the deficit of the enzyme leads
to chronic accumulation of excitotoxic glutamate in astrocytes and the extracellular space, possibly
resulting in the perturbation of the glutamine-glutamate-GABA cycle [82].
Decreased GS activity was also reported in patients who underwent orthotopic lung transplantation
for various pulmonary diseases [106]. In a retrospective study, 6 of 145 patients developed severe
hyperammonemia following lung transplantation [106]. It was discussed that the hyperammonemia
was related to hepatic GS deficiency, which could be confirmed by reduced enzymatic activities of
12% and 28% of the mean value of controls in two cases [106,107]. Among all of the patients, levels of
plasma ammonia were elevated to a maximum of 5000 µmol/L (normal < 50) [107], which makes it
likely that other factors were contributing as well.
Additionally, since glutamine was found to be an energized substrate for numerous types of
tumoral cells [108,109], and GS expression levels were related with survival in some patients [110,111],
GS could be a possible pharmacological target in some cancers. For more information about glutamine
metabolism in cancer, the reader is referred to the following reviews [109,112].
8. Management of Patients with Inherited Glutamine Synthetase Deficiency
The management of patients with GS deficiency is not remedial, but supportive, and depending
on the symptoms. Focus is on treatment of epilepsy and on supportive measures to allow the best
possible development, despite the disease. As this disorder was devastating in all three patients,
palliative care should also be considered early in the course of such patients.
In addition, there are specific considerations related to the metabolic phenotype. For instance,
dietary interventions have not yet been tested for this disease. One rationale would be to use protein
restriction to alleviate chronic hyperammonemia, but the efficiency of this measure should be evaluated.
Since the normalization of glutamine levels was considered to be the prerequisite for improvement
of brain function [5], specific enteral glutamine supplementation was applied over a period of four
weeks in one GS-deficient patient (patient 3 in Table 1). Glutamine supplementation was already
proven safe in healthy volunteers, and had a positive effect in clinical trials—e.g., for brain development
in supplemented preterm children [14,113]. The aim of treatment in the GS-deficient patient was to
progressively increase the concentration of glutamine while avoiding its adverse effects, namely
the potentially damaging consequences of high ammonia levels in CSF (and of high levels of CSF
glutamate, described above).
The patient remained clinically stable during the entire trial. He was provided with L-glutamine
via a gastrostomy tube or parenteral route (starting with a dose of 17 mg/kg/day and increasing
progressively to 1020 mg/kg/day). Enteral glutamine supplementation was sufficient to establish
and maintain normal plasma glutamine levels and increased CSF glutamine levels, which were
concomitant with an improvement of the patient’s alertness and emotional expressions. EEG recordings
were improved in both awake and sleeping states; in the MRS of basal ganglia, brain glutamine
concentrations were markedly increased, reflecting a relevant transfer of glutamine into the brain
tissues [5]. Ammonia levels in the plasma and CSF did not increase, but remained stable;
nevertheless, in case of severely impaired hepatic function, treatment with high dose glutamine
is not recommended [114]. Additionally, since high doses of glutamine could yield mitotoxic levels of
ammonia through the reaction of PAG in the astrocytes [115] (Figure 3), it is recommended to start
with low-dose glutamine supplementation followed by gradual increases of the dose [5].
Glutamine concentrations remained low in comparison to the normal range for the age, but this
may indicate an enhanced glutamine utilization by the glutamatergic and GABAergic neurons, as
supported by the improvements in background EEG activity and alertness.
Baseline MRI showed increased white matter intensity on T2 weighted images, reduced white
matter volume, and atrophic basal ganglia, and did not improve during the four weeks of the trial.
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The increase of NAD+ in leucocytes (described above) also supported the beneficial effects of the
treatment at the cellular level [5,31].
These results corroborate that enteral glutamine supplementation increased the supply of
glutamine throughout the body. For future patients, glutamine supplementation should be considered
as early as possible in order to prevent the devastating natural course of the disease. In addition, NAD+
supplementation may also be beneficial, but should be tested prospectively.
9. Conclusions
In summary, we report here the clinical course of the three patients diagnosed to date with
an inherited defect in GS. This ultra-rare disease is characterized by severe neonatal encephalopathy
with decreased levels of glutamine in body fluids, and is associated with chronic hyperammonemia.
GS deficiency is an ultra-rare but probably underdiagnosed disorder that may escape diagnosis
because decreased plasma and urine glutamine levels may not be noted as reliably as increased
levels. Therapeutic intervention in a single patient using glutamine supplementation demonstrated
the feasibility of correcting systemic glutamine deficiency without worsening the pre-existing
hyperammonemia or provoking toxic CSF glutamate levels. The severity of GS deficiency also
seems to be related to decreased NAD+ levels, which were detected in the patient’s cells and were
normalized upon glutamine supplementation. For future patients, glutamine supplementation should
be administered as early as possible in order to prevent the devastating natural course of the disease.
Since GS is a key enzyme for many metabolic pathways, its secondary deficiency, resulting from
posttranslational modifications, can also contribute to the development of a broad scope of human
neurodegenerative and neurological diseases.
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